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Time to Apply the 3 R’s to Virus 
Testing?
Rebecca Sheets, Grimalkin Partners
ECI VTVI,  Albufeira, Portugal, June13, 2016
Disclaimer
• This presentation represents solely the opinions of the 
speaker and does not reflect any U.S. government 
policies or the opinions of the National Institutes of Health 
or the Food & Drug Administration.
Context
• 3 R’s – reduce, refine, or replace the use of animals in product testing
• Lack of regulatory convergence
• EU has directive (mandatory law) requiring that 3 R’s be applied; whenever in 
vitro methods are available, in vivo tests should not be used. 
• Illegal for European companies to not comply, but if they sell to US or other countries 
that still require in vivo tests, they are in catch 22.
• EDQM is changing EP in consideration of data from study I will present
• US has public law to REVIEW their regulations to see where 3 R’s could be applied, 
but only policy to actually apply 3 R’s
• Despite data I will present, FDA  has not changed requirements (policy is not translated 
into action) 
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Introduction
• Routine Tests for Adventitious Viruses
• in vivo with mortality or morbidity read-outs
• In tissue culture with CPE & HAd read-outs
• Transmission Electron Microscopy
• Specific PCRs for selected viruses
• PCR-based reverse transcriptase assay
• (infectivity for retroviruses)
• Bovine, porcine viruses (9 CFR tests in cell culture with CPE, HAd, and IFA read-outs)
• (MAP, RAP, HAP – in vivo or PCR)
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“Routine” Adventitious Virus Tests
Purpose of Work
• Provide regulators and manufacturers with information needed for 
decision-making
• Such info normally comes from assay validation
• Provide baseline data to serve as basis of comparison for new 
methods
• Provide protocols and viral stocks to permit “direct” comparisons by 
developers of new methods
• Determine “value added” by in vivo methods in consideration of       
3 R’s policy
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“Routine” Adventitious Virus Tests
Breadth & Sensitivity
• These tests were developed for clinical diagnostics in mid-20th 
century
• Initially used to detect SPECIFIC adventitious agents
• Use expanded to broad general screening assays
• Breadth/sensitivity had not been systematically assessed & 
published
• Not validated in the manner currently developed assays would 
be required
• No regulatory requirements to do so and costly to do
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“Routine” Adventitious Virus Tests
Implementation Phase
• The prime contractor, Advanced BioScience Laboratories, 
awarded task to Charles River Labs to implement this project
• Compliant with Good Laboratory/Manufacturing Practices
• Experienced with routine adventitious agent testing
• In vivo and in vitro capabilities
• Virology expertise to prepare and characterize viral stocks required
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Implementation Phase (2)
• Viral stocks prepared in cell culture
• Titrated in production cell line or positive control cell line
• Characterized for purity & identity
• In vivo testing
• Test at highest concentration for breadth
• If positive, sensitivity determined by titration (dilutions)
• In vitro testing
• Breadth and sensitivity assessed simultaneously 8
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Results and Conclusions
The results can answer questions 
such as:
• Is using two human cell lines 
useful? 
• Is a 14-day in vitro test sufficient or 
are 28 days needed?
• Is sub-passage useful for suckling 
mouse test sensitivity? 
• Which is more sensitive – in vitro or 
in vivo? 
• Yes, MRC-5 & HeLa had different 
sensitivities, sometimes one was better, 
sometimes the other
• 28 days more sensitive in some cases
• No, for the viruses tested
• With the exception of flu & VSV, the in 
vitro tests were always more sensitive, 
generally by logs, sometimes the 
difference between detecting & not 
detecting
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Results and Conclusion
Table 4.  In Vitro Limit of Detection of Research Virus Stocks
Virus
Vero MRC-5 HeLa Other
CPE HA/HAD/IFa CPE HA/HAD/IFa CPE HA/HAD/IFa CPE HA/HAD/IFa
Adenovirus 5
Adenovirus 41
BVDV
BoPIV-3 nd b nd
Coxsackie A16
Coxsackie B3 nd nd nd
Echovirus 11 nd nd
Influenza A nd nd
HSV-1 nd nd
Measles nd nd
Mumps nd nd
Rhinovirus 2 nd nd nd nd nd
Rubella
Simian CMV
SV-40 nd nd
VSV nd nd nd nd nd
aAll virus-infected cultures were tested for hemadsorption activity except BVDV (immunofluorescence), influenza A and rubella 
(hemagglutination) and rhinovirus 2 and VSV (CPE only)
bNot done
b Detection by immunofluorescence
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0.001 ID
0.01 ID 
0.1 ID 
1.0 ID 
10.0 ID 
100.0 ID 
1,000.0 ID 
100,000.0 ID 
Undiluted
Undetected
“Routine” Adventitious Virus Tests
Results
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“Routine” Adventitious Virus Tests
Outcomes/Deliverables
• Viral stocks will be made available through the NIAID/DAIDS 
Reagent Resource Support Program for AIDS Vaccine 
Development
• http://www.niaid.nih.gov/topics/hivaids/research/vaccines/resources/re
agent/pages/default.aspx
• A research repository, not a regulatory authority control lab reagent 
repository
• Not international reference materials, but research reagents
• Protocols for virus preparation, titration, and for in vivo and in vitro 
test methods will also be made available
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